ImmunityBio shares rose 3% pre-market after an interim analysis showed ANKTIVA combined with BCG significantly improved bladder cancer responses. At nine months, 84% of patients on the combo maintained a complete response versus 52% on BCG alone. With no major safety concerns, ImmunityBio plans to submit a Biologics License Application by Q4 2026.